Last reviewed · How we verify
Evolocumab or Alirocumab
At a glance
| Generic name | Evolocumab or Alirocumab |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS) (NA)
- PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy (PHASE2, PHASE3)
- Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
- Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
- Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
- Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients (PHASE4)
- Genetic Testing and Motivational Counseling for FH (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evolocumab or Alirocumab CI brief — competitive landscape report
- Evolocumab or Alirocumab updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI